metricas
Medicina Clínica (English Edition) Incidence of non-melanoma skin cancer in patients treated with psoralen and ultr...
Journal Information
Vol. 152. Issue 12.
Pages e67-e74 Pages 473-518 (June 2019)
Cite
Cite
Share
Download PDF
More article options
Visits
659
Vol. 152. Issue 12.
Pages e67-e74 Pages 473-518 (June 2019)
Original article

Incidence of non-melanoma skin cancer in patients treated with psoralen and ultraviolet A therapy

Incidencia de cáncer cutáneo distinto del melanoma en pacientes tratados con PUVA oral
Visits
659
José María Ortiz Salvadora,
Corresponding author
josema.ortiz.salvador@gmail.com

Corresponding author.
, Amparo Pérez-Ferriolsa,b, Víctor Alegre de Miquela,b, Martina Saneleuterio Temporalc, Juan José Vilata Corella,b
a Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain
b Facultad de Medicina, Universitat de València, Valencia, Spain
c Hospital Universitario y Politécnico La Fe, Valencia, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Introduction

Studies reporting incidences of non-melanoma skin cancer (NMSC) are heterogeneous, depend on the geographic area of the studied population and are often short-term. The aim of this study is to determine the incidence of NMSC in patients treated with oral PUVA therapy in the Mediterranean area.

Material and methods

A retrospective, observational study was carried out with a sample of 234 patients treated with systemic PUVA between 1982 and 1996, carrying out a historical follow-up until May 2017. The incidence density rate of CCNM (crude and adjusted) was calculated by direct standardisation. The incidence of CCNM was compared with that reported in the general population in a similar geographical area.

Results

50 neoplasms were diagnosed in 22 patients. The prevalence of CCNM in patients treated with phototherapy was 10.3%. The mean follow-up time was 21 years. The crude-adjusted incidence density rate of CCNM was 554.4–183.9 cases/100,000 treated patients per year. The crude-adjusted incidence density rate of basal cell carcinoma was 352.3–111.2 cases/100.000 patients and of squamous cell carcinoma was 229–77.7 cases/100,000 patients.

Conclusion

PUVA therapy is associated with an increased risk of CCNM in the Mediterranean population.

Keywords:
PUVA therapy
Phototherapy
Skin cancer
Basal cell carcinoma
Squamous cell carcinoma
Carcinoma
Resumen
Introducción

Los trabajos que determinan la incidencia de cáncer cutáneo no melanoma (CCNM) en la población tratada con psoralenos orales+UVA son heterogéneos, dependen de la localización geográfica de la población estudiada y tienen períodos de seguimiento cortos. El objetivo del trabajo es determinar la seguridad a largo plazo de la PUVAterapia y en concreto determinar la incidencia de CCNM en los pacientes tratados con PUVAterapia oral en el área mediterránea.

Material y método

Se ha realizado un estudio longitudinal de seguimiento retrospectivo, recogiendo 234 pacientes tratados con PUVA sistémico entre 1982 y 1996 con un seguimiento hasta mayo de 2017. Se ha calculado la densidad de incidencia de CCNM bruta y ajustada por edad mediante estandarización directa.

Resultados

En 22 pacientes se diagnosticaron 50 neoplasias. La prevalencia de CCNM en pacientes tratados con fototerapia fue del 10,3%. El tiempo medio de seguimiento fue de 21 años. la densidad de incidencia bruta-ajustada de CCNM fue de 554,4-183,9 casos/100.000 pacientes tratados-año. La densidad de incidencia bruta-ajustada de carcinoma basocelular fue de 352,3-111,2 casos/100.000 pacientes y la de carcinoma epidermoide de 229-77,7 casos/100.000 pacientes.

Conclusión

La incidencia de cáncer cutáneo en los pacientes tratados con PUVAterapia es superior a la descrita en la población mediterránea.

Palabras clave:
PUVAterapia
Fototerapia
Cáncer de piel
Carcinoma basocelular
Carcinoma epidermoide
Carcinoma

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
P. Wolf.
Psoralen-ultraviolet A endures as one of the most powerful treatments in dermatology: reinforcement of this “triple-product therapy” by the 2016 British guidelines.
Br J Dermatol, 174 (2016), pp. 11-14
[2]
E. Archier, S. Devaux, E. Castela, A. Gallini, F. Aubin, M. Le Maitre, et al.
Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.
J Eur Acad Dermatol Venereol, 26 (2012), pp. 22-31
[3]
J.M. Carrascosa, J. Gardeazábal, A. Pérez-Ferriols, A. Alomar, P. Manrique, M. Jones-Caballero, et al.
Consensus document on phototherapy: PUVA therapy and narrow-band UVB therapy.
Actas Dermosifiliogr, 96 (2005), pp. 635-658
[4]
M. Segi, I. Tōhoku Daigaku, K. Nippon Taigan.
Cancer mortality for selected sites in 24 countries.
Sendai Tohoku Univ Sch Public Health, (1960),
[5]
R.S. Stern, E.J. Lunder.
Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis.
Arch Dermatol, 134 (1998), pp. 1582-1585
[6]
R.S. Stern, K.T. Nichols, L.H. Väkevä.
Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.
N Engl J Med, 336 (1997), pp. 1041-1045
[7]
R.S. Stern, E.J. Liebman, L. Väkevä.
Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study.
J Natl Cancer Inst, 90 (1998), pp. 1278-1284
[8]
R.S. Stern.
The risk of melanoma in association with long-term exposure to PUVA.
J Am Acad Dermatol, 44 (2001), pp. 755-761
[9]
R.S. Stern.
The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.
J Am Acad Dermatol, 66 (2012), pp. 553-562
[10]
T. Henseler, E. Christophers, H. Hönigsmann, K. Wolff, Skin Tumors in the European PUVA Study.
Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis.
J Am Acad Dermatol, 16 (1987), pp. 108-116
[11]
T. Henseler, E. Christophers.
Risk of skin tumors in psoralen- and ultraviolet A-treated patients.
Natl Cancer Inst Monogr, 66 (1984), pp. 217-219
[12]
N.H. Cox, S.K. Jones, D.J. Downey, E.J. Tuyp, J.L. Jay, H. Moseley, et al.
Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study.
Br J Dermatol, 116 (1987), pp. 145-152
[13]
H. Hönigsmann, K. Wolff, F. Gschnait, W. Brenner, E. Jaschke.
Keratoses and nonmelanoma skin tumors in long-term photochemotherapy (PUVA).
J Am Acad Dermatol, 3 (1980), pp. 406-414
[14]
A. Lassus, T. Reunala, J. Idänpää-Heikkilä, T. Juvakoski, O. Salo.
PUVA treatment and skin cancer: a follow-up study.
Acta Derm Venereol, 61 (1981), pp. 141-145
[15]
E. Lobel, K. Paver, R. King, J. Le Guay, K. Poyzer, O. Wargon.
The relationship of skin cancer to PUVA therapy in Australia.
Australas J Dermatol, 22 (1981), pp. 100-103
[16]
R. Lindskov.
Skin carcinomas and treatment with photochemotherapy (PUVA).
Acta Derm Venereol, 63 (1983), pp. 223-226
[17]
N. Vilar-Coromina, J. Miró-Queralt, A. Cano-Bautista, L. Vilardell-Gil, P. Torres Babié, R. Marcos-Gragera.
Non-melanoma skin cancer: incidence time trends analysis in Girona Spain, 1994–2007.
Med Clin (Barc), 137 (2011), pp. 145-151
[18]
B. Lindelöf, B. Sigurgeirsson, E. Tegner, O. Larko, A. Johannenson, B. Berne, et al.
PUVA and cancer risk: the Swedish follow-up study.
Br J Dermatol, 141 (1999), pp. 108-112
[19]
I. Bruynzeel, W. Bergman, H.M. Hartevelt, C.C. Kenter, E.A. van de Velde, A.A. Schothorst, et al.
“High single-dose” European PUVA regimen also causes an excess of non-melanoma skin cancer.
Br J Dermatol, 124 (1991), pp. 49-55
[20]
A. Hannuksela-Svahn, E. Pukkala, E. Läärä, K. Poikolainen, J. Karvonen.
Psoriasis, its treatment, and cancer in a cohort of Finnish patients.
J Invest Dermatol, 114 (2000), pp. 587-590
[21]
A. Maiorino, C. de Simone, F. Perino, G. Caldarola, K. Peris.
Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy.
J Dermatol Treat, 27 (2016), pp. 443-447
[22]
T.E.C. Nijsten, R.S. Stern.
The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study.
J Invest Dermatol, 121 (2003), pp. 252-258
asdasdasd
Article options
Tools